Related Experiment Video
Updated: May 31, 2026
08:36
The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
Published on: April 19, 2024
What Determines the Clinical Course and Outcome of DPPX Encephalitis? A Systematic Review
Somdattaa Ray1, Tinku Thomas2, Vikram Kamath3
1Department of Neurology, St John's Medical College Hospital, Bangalore, India.
Movement Disorders Clinical Practice
|May 29, 2026
Summary
Dipeptidyl peptidase like protein 6 (DPPX) encephalitis prognosis is linked to hyperekplexia. Early recognition of hyperekplexia aids in predicting the need for long-term immunotherapy and disease course.
Area of Science:
- Neurology
- Immunology
- Systematic Review
Background:
- Dipeptidyl peptidase like protein 6 (DPPX) encephalitis is a rare autoimmune disorder with diverse clinical presentations and variable outcomes.
- Understanding its course and treatment response is crucial for patient management.
Purpose of the Study:
- To systematically review the clinical course of DPPX encephalitis.
- To evaluate the effectiveness of various immunotherapies.
- To identify predictors of clinical outcome and relapse.
Main Methods:
- A systematic literature search was conducted on PubMed and Web of Science.
- Univariate analysis and multiple regression modeling were employed to analyze outcome and relapse predictors.
- Data from 66 patients with treatment details were analyzed.
Main Results:
- Favorable clinical improvement was observed in 74.24% of patients.
- Good response to first-line immunotherapy predicted favorable outcomes in patients without hyperekplexia.
- CSF abnormality and hyperekplexia were associated with a higher relapse risk.
Conclusions:
- Hyperekplexia recognition is vital for prognostication, guiding immunotherapy duration and predicting disease course.
- A subgroup of DPPX encephalitis patients may experience a monophasic illness.
Related Concept Videos
01:26Encephalitis ll: Pathophysiology
Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
01:19Encephalitis l: Introduction
Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
01:30Acute Pancreatitis II: Clinical Manifestations and Management
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:21Acute Pancreatitis II: Pathophysiology
The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...
01:26Bacterial Meningitis II: Pathophysiology
Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...